Mineralys outlines lorundrostat U.S. launch plans ahead of December 22, 2026 PDUFA

Earnings Call Insights: Mineralys Therapeutics (MLYS) Q1 2026

MANAGEMENT VIEW

*
“During the first quarter, the FDA accepted the NDA for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs and assigned a PDUFA target date of December 22, 2026.” (President, CEO & Director Jon Congleton)

*
“From an operational perspective, we're focused on preparing lorundrostat for a successful launch in the United States, while we continue to evaluate partnering opportunities and consider the next steps in the clinical development of lorundrostat.” (President, CEO & Director Congleton)

*
“Collectively, these 5 trials demonstrated that lorundrostat delivers clinically meaningful reductions in blood pressure, is well tolerated and maintains a durable response across diverse patient populations.” (President, CEO & Director Congleton)

*
“We ended the quarter with cash, cash equivalents and investments of $646.1 million as of March 31, 2026, compared to $656.6 million as of December 31, 2025.” (CFO & Secretary Adam Levy)

*
“So it's all about sequencing, Richard, so that fourth line as the entry point.” (Chief Commercial Officer Eric Warren)

OUTLOOK

*
“As we move towards our PDUFA target date, our operational focus will continue to be on preparing lorundrostat for commercial success.” (President, CEO & Director Congleton)

*
“The launch of lorundrostat, if approved, will be initially focused on this population with the highest need.” (President, CEO & Director Congleton)

*
“The opportunity will be to gain that experience, gain that confidence and then make that transition to the third line using that comorbid condition as a bridge.” (Chief Commercial Officer Warren)

*
“We believe that our current cash, cash equivalents and investments will be sufficient to fund our planned clinical trials and regulatory activities as well as support corporate operations into 2028.” (CFO Levy)

FINANCIAL RESULTS

*
“R&D expenses for the quarter ended March 31, 2026, were $24.4 million compared to $37.9 million for the quarter ended March 31, 2025.” (CFO Levy)

*
“G&A expenses were $21 million for the quarter ended March 31, 2026, compared to $6.6 million for the quarter ended March 31, 2025.” (CFO Levy)

*
“Total other income net was $6 million for the quarter ended March 31, 2026, compared to $2.2 million for the quarter ended March 31, 2025.” (CFO Levy)

*
“Net loss was $39.3 million for the quarter ended March 31, 2026, compared to $42.2 million for the quarter ended March 31, 2025.” (CFO Levy)

Q&A

*
Michael DiFiore, Evercore: “In a scenario where Mineralys launches lorundrostat itself without a partner, will you conduct any more significant R&D activity or business development?” President Congleton: “we're going to continue to look at ways that we increase value for lorundrostat and Mineralys... we'll continue to look at opportunities to build value from a clinical development perspective. And we'll continue to look at opportunities to expand the value of lorundrostat through business development.”

*
Michael DiFiore, Evercore: “as you near the day 120 safety update... can you comment on whether safety remains consistent with the past and whether there's updated plans to publish data from the OLE?” President Congleton: “we continue to be very confident in the safety profile of lorundrostat... we'll be looking to get that long-term data published in due course.”

*
Jin Law, Goldman Sachs: “Do you get a sense that you need to compete with AZ on preferred or exclusive access with payers...?” Chief Commercial Officer Warren: “having parity access is something that's a focus for us.”

*
Seamus Fernandez, Guggenheim Securities: “What is it that you're looking for at this point in a potential partner...?” President Congleton: “we're interested in finding the right partner... we're not in a position to really provide color or specifics around the level of dialogue, the timing, the structure.”

*
Jason Gerberry, BofA Securities: “how are you thinking about like the physician segments that you think are going to be the most likely to drive early adoption...?” President Congleton: “primary care... but cardiologists as well... and... nephrology as well.”

*
Tara Bancroft, TD Cowen: “can you tell us more about how you'll react to WACC pricing... could you launch with a lower WACC price?” President Congleton: “it's really early to opine too much on that... we'll see where AstraZeneca comes in with pricing... there are a lot of different levers we could pull from contracting to what we do with our patient assistance program.”

SENTIMENT ANALYSIS

*
Analysts’ tone was neutral-to-skeptical on commercialization execution and partnering timing, with questions framed around competitive access and deal progress, including “address the elephant in the room” and “metric what is the timing for either selection of a partner or that go-it-alone.” (Seamus Fernandez, Guggenheim Securities)

*
Management’s tone was confident on regulatory progress and launch readiness, while cautious on topics tied to uncertain outcomes, including “we continue to be very confident in the safety profile of lorundrostat” and “it's really early to opine too much on that.” (President Congleton)

*
Versus the prior quarter, the current call emphasized NDA acceptance as a recent milestone and repeated operational readiness themes, including “we're focused on preparing lorundrostat for a successful launch in the United States,” following earlier positioning that the Q4 call was “on the heels of our announcing the FDA's acceptance of the NDA.” (President Congleton)

QUARTER-OVER-QUARTER COMPARISON

*
In Q1 2026, management centered the narrative on the FDA timeline, stating the NDA “assigned a PDUFA target date of December 22, 2026,” while Q4 2025 presented the same PDUFA date as part of the acceptance announcement and spent more time on Explore-OSA topline results, including “lorundrostat did not demonstrate a clinically meaningful difference relative to placebo on the primary endpoint, AHI.” (President, CEO & Director Congleton)

*
Q1 2026 discussion of commercial strategy tightened around a “fourth line” entry and payer “parity access,” while Q4 2025 described a broader targeting framework (including “it's about 60,000 physicians that are responsible for half of the scripts third line or later”) without providing headcount details. (President Congleton; Chief Commercial Officer Warren)

*
Q1 2026 financial commentary highlighted a step-up in G&A tied to launch preparation, while Q4 2025 described 2025 as “a heavy lift on R&D” and indicated “less R&D activity in 2026 than we had in 2025,” reflecting the shift from pivotal trial execution to pre-commercial and regulatory work. (CFO Levy)

RISKS AND CONCERNS

*
“What language, what portions of those studies get into the actual label, that will be part of negotiations with the FDA.” (President, CEO & Director Congleton)

*
“We'll see where AstraZeneca comes in with pricing... we'll evaluate what makes sense for lorundrostat.” (President Congleton)

*
“we're not in a position to really provide color or specifics around the level of dialogue, the timing, the structure” on partnering. (President Congleton)

FINAL TAKEAWAY

Management highlighted FDA acceptance of the lorundrostat NDA with a December 22, 2026 PDUFA date and described parallel efforts to prepare a U.S. launch focused initially on fourth-line resistant hypertension, maintain payer engagement aimed at “parity access,” and continue partnering discussions without providing timing specifics. The company reported $646.1 million in cash, cash equivalents and investments at quarter-end and stated that resources are expected to support operations into 2028, while financials reflected lower R&D versus the prior year quarter and higher G&A associated with readiness activities.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/mlys/earnings/transcripts]

MORE ON MINERALYS THERAPEUTICS

* Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4900022-mineralys-therapeutics-inc-mlys-q1-2026-earnings-call-transcript]
* Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval [https://seekingalpha.com/article/4882264-mineralys-big-pharma-threatens-to-undermine-likely-hypertension-drug-approval]
* Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4881913-mineralys-therapeutics-inc-mlys-q4-2025-earnings-call-transcript]
* Mineralys Therapeutics GAAP EPS of -$0.47 misses by $0.02 [https://seekingalpha.com/news/4587551-mineralys-therapeutics-gaap-eps-of-0_47-misses-by-0_02]
* Mineralys targets December 2026 lorundrostat approval as payer engagement and data drive launch strategy [https://seekingalpha.com/news/4564094-mineralys-targets-december-2026-lorundrostat-approval-as-payer-engagement-and-data-drive]